Vizimpro

Vizimpro Indications/Uses

dacomitinib

Manufacturer:

Distributor:

Zuellig Pharma

NEW Brand Resources

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Full Prescribing Info

Indications/Uses

VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations [see Patient Selection under Dosage & Administration].

Continue with Google

Already a member? Sign in

Vizimpro Indications/Uses

dacomitinib

Manufacturer:

Pfizer

Distributor:

Zuellig Pharma